TrialScientific reports2015

Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR).

Monica Ganzinelli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.